AWM
AKBA icon

Ameliora Wealth Management’s Akebia Therapeutics AKBA Stock Holding History

Ameliora Wealth Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,615
Closed -$20.4K – 224
2025
Q2 		$20.4K Hold
5,615
– – 0.01% 177
2025
Q1 		$10.8K Hold
5,615
– – ﹤0.01% 213
2024
Q4 		$10.7K Hold
5,615
– – ﹤0.01% 207
2024
Q3 		$7.41K Hold
5,615
– – ﹤0.01% 144
2024
Q2 		$5.73K Hold
5,615
– – ﹤0.01% 169
2024
Q1 		$10.3K Buy
+5,615
New +$8.98K ﹤0.01% 173

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Ameliora Wealth Management's AKBA Position: Q3 2025 in Review

Ameliora Wealth Management sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 5,615 shares — an estimated $20.4K sold.

Ameliora Wealth Management first reported a position in AKBA in Q1 2024 and held it in 6 quarters. The position peaked at $20.4K in Q2 2025. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

  • Ameliora Wealth Management reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ameliora Wealth Management sold 5,615 Akebia Therapeutics shares in Q3 2025, an estimated $20.4K.
  • Ameliora Wealth Management first reported a position in Akebia Therapeutics in Q1 2024 and held it in 6 quarters.
  • Ameliora Wealth Management's Akebia Therapeutics position peaked at $20.4K in Q2 2025.
  • 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on Ameliora Wealth Management's 13F filing for Q3 2025, filed 12 Nov 2025.